Cabozantinib(Cabometyx)

Cabozantinib is a prescription medicine that targets MET, AXL and VEGFR. It was first approved by the United States Food and Drug Administration (FDA) on November 29, 2012, and must be taken strictly in accordance with a healthcare provider’s instructions.

Certificates related to Lucius

Drug Testing Report

Drug Approval Certificate

Targets

MET, AXL and VEGFR

Dosage and Administration

Route and frequency of administration of Cabozantinib: Oral administration, once daily, 60 mg per dose.

The dosage of Cabozantinib should be adjusted according to the patient's actual condition. For specific adjustments, please consult a doctor and strictly follow medical advice.

Recommended reading: Dosage and Administration of Cabozantinib

Adverse Reactions

Common adverse reactions: Fatigue, nausea and vomiting, constipation, etc.

Severe adverse reactions: Hemorrhage, hypertension, heart disease, etc.

Reference article: Adverse Reactions of Cabozantinib

Use in Special Populations

Pregnancy: Pregnant or planning to become pregnant. Cabozantinib may cause harm to the fetus in your womb.

Lactation: Lactating or planning to breastfeed. It is unknown whether Cabozantinib enters breast milk. Do not breastfeed during treatment and for 4 months after the last dose of Cabozantinib.

General Precautions

1. Instruct patients to read the FDA-approved Patient Medication Guide (Patient Information).

2. Instruct patients not to take Cabozantinib with food. Emphasize:

Swallow Cabozantinib capsules whole with a full glass (at least 240 mL) of water; do not open or crush the capsules.

Swallow Cabozantinib tablets whole with a full glass (at least 240 mL) of water; do not crush, chew, or split the tablets.

Avoid eating grapefruit or drinking grapefruit juice while taking this medication.

3. If a dose of Cabozantinib is missed, take it as soon as remembered if the next scheduled dose is ≥12 hours away; take the next dose as scheduled and do not take the missed dose if the next scheduled dose is <12 hours away.

from FDA，2023.09